U.S. Markets closed

AVEO Pharmaceuticals, Inc. (AVEO)

NASDAQ Capital Market - NASDAQ Capital Market Delayed Price. Currency in USD
Add to watchlist
3.510.00 (0.00%)
At close: 4:00PM EDT

3.51 0.00 (0.00%)
After hours: 7:57PM EDT

People also watch
ACRXPBMDAEZSANTHCLSN
Full screen
Previous Close3.51
Open3.48
Bid3.51 x 100
Ask3.69 x 500
Day's Range3.41 - 3.69
52 Week Range0.50 - 3.69
Volume6,007,562
Avg. Volume6,291,232
Market Cap539.11M
Beta1.40
PE Ratio (TTM)-9.24
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
    Capital Cube8 days ago

    AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017

    Categories: Yahoo FinanceGet free summary analysis AVEO Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of AVEO Pharmaceuticals, Inc. – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company and Merrimack Pharmaceuticals, Inc. (BIIB-US, REGN-US, ARQL-US, BMY-US, ... Read more (Read more...)

  • AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected
    Zacks14 days ago

    AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected

    AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.

  • Associated Press14 days ago

    AVEO reports 2Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs, came to 8 cents per share. The cancer drug company posted revenue of $351,000 ...